Latest leukemia Stories

Analysis Evaluates Response Rates in Patients with 17p Deletion, Fludarabine-Refractory CLL NORTH CHICAGO, Ill., June 17, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), and in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). High-risk CLL patients...

- Pooled Analysis from Four Phase 1 and Phase 2 Clinical Studies Demonstrates Persistence of Treatment - SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from a pooled analysis of data from completed Phase 1 and 2 studies of pacritinib, an oral JAK2/FLT3 inhibitor, demonstrating the safety and tolerability profile of pacritinib in patients with myelofibrosis. An integrated safety analysis of four completed Phase 1...

SUNNYVALE, Calif., June 16, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL). Pharmacyclics sponsored both studies and is jointly developing ibrutinib with Janssen...

Data presented at the European Hematology Association (EHA) Annual Congress RARITAN, N.J., June 16, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen), today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, shows efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL). The studies...

Two locals, Manny Camara and Karen Routt have been named the winners of this year’s Silicon Valley Man & Woman of the Year for The Leukemia & Lymphoma Society’s (LLS) – Greater Bay Area Chapter. San Jose, CA (PRWEB) June 13, 2013 Manny Camara and Karen Routt have been named as this year’s Silicon Valley Man & Woman of the Year for The Leukemia & Lymphoma Society’s (LLS)—Greater Bay Area Chapter. During a spirited ten-week cancer fundraising period beginning...

Firm’s Senior Manager of Corporate Social Responsibility named 2013 LLS ‘Woman of the Year,’ leading the National Capital Chapter to set a new fundraising record of $1.145 million. McLean, Virginia (PRWEB) June 12, 2013 MorganFranklin Consulting, a leading business consulting and technology solutions company based in McLean, Va., and London, announced that Jeana Foster, the firm’s Senior Manager of Corporate Social Responsibility (CSR), has been named the 2013 Leukemia &...

Spirited 10-week fundraising competition introduced powerful new techniques to raise money for vital blood cancer research and patient services. San Francisco, CA (PRWEB) June 11, 2013 The Greater Bay Area Chapter of The Leukemia & Lymphoma Society (LLS) will announce the results of its 23rd annual “Man & Woman of the Year” campaign – in which candidates introduced innovative cancer fundraising techniques that garnered headlines around the world – at the Grand Finale at...

The B+ (Be Positive) Foundation reaches out to 7 cities where major breast cancer walks were dropped in hopes of rallying support to fight childhood cancer. Wilmington, DE (PRWEB) June 10, 2013 In light of a prominent breast cancer organization’s recent announcement of canceled three day walks in seven major cities, The B+ Foundation is now inviting those cities to join the fight against childhood cancer by spearheading fundraisers in their area. Chris McDonough, Co-Founder of The...

A study led by St. Jude Children's Research Hospital shows epigenetic changes that turn genes on and off are as unique as alterations in DNA and may be as important in causing the most common childhood cancer MEMPHIS, Tenn., June 10, 2013 /PRNewswire-USNewswire/ -- Changes in an epigenetic mechanism that turns expression of genes on and off may be as important as genetic alterations in causing pediatric acute lymphoblastic leukemia (ALL), according to a study led by scientists...

MRI scans of children who have had chemotherapy can detect early changes in their hearts finds research in biomed Central's open access journal Journal of Cardiovascular Magnetic Resonance. Chemotherapy with anthracyclines, such as Doxorubicin, is one of the most effective treatments against many types of cancer, including leukaemia and Hodgkin's lymphoma, breast, lung, and ovarian cancer. However it can also lead to irreversible heart damage, which may not be apparent until several years...